Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Cedirogant in Hepatic Impairment
NCT05376839Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cedirogant in psoriasis (4 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration up to 18 Days, Time to Maximum Observed Plasma Concentration up to 18 Days and 1 more. Started Jul 2022; status: terminated.
02
Drugs
cedirogant
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05376839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376839.